Do you offer local treatment to the breast primary in patients with de novo oligometastatic hormone positive breast cancer?  

How has your practice been impacted by the ECOG 2108 (Khan et al. ASCO 2020 Abst LBA2)? Are there sites or distribution of disease that prompt you to treat?



Answer from: Medical Oncologist at Academic Institution